WP1
Technical and clinical specifications of the PLS system were defined, resulting in detailed requirement lists (D1.1). Computational models for fetal physiology, circulation, and growth were verified, with sensitivity analyses performed. A wireless connection to the manikin's sensor output was established, and modules were adapted to fetal piglet physiology to support artificial placenta development. Work from WP1 is now integrated into WP6, with results published in peer-reviewed journals and a PhD thesis.
WP2
Development focused on the liquid-filled chamber (LFC) and liquid-filled lungs (LFL), optimizing prototypes (D2.1) and umbilical cord ports (D2.2). Trachea tubes (D2.3) and protocols for harvesting and maintaining umbilical cords were finalized, with a bioreactor designed to replicate physiological pressures. Recent efforts included improving LFC adaptability, sealing, filtration, and analyzing neonatal blood hemolysis. These are now ready for WP6 integration.
WP3
Advanced fetal and maternal manikins were developed with moving limbs, ribcage, and embedded sensors (e.g. temperature, air bubbles, cyanosis). Transfer devices for safe handling were prototyped, including a crib for cannulation. These innovations support WP6 integration. Results were disseminated in publications, including a concept PhD thesis.
WP4
A two-chamber oxygenator with minimal volume and low flow resistance was developed and tested (D4.1–D4.3). Recent enhancements improved gas transfer performance and pressure resistance. Tests aligned with ISO 7199 standards yielded excellent results, with findings partially published and a related PhD thesis underway.
WP5
A hybrid monitoring device combining Diffuse Correlation Spectroscopy (DCS) and Time Domain Near Infrared Spectroscopy (TD-NIRS) was optimized and validated (D5.3 D5.4). Modelling work led to a cerebral autoregulation model. Investigations into fECG measurements through the LFC's insulating layer concluded feasibility limitations with current electrodes.
WP6
Subsystem integration was finalized (month 51), verifying compliance with WP1 requirements. The verification and validation cycle (D6.1) demonstrated that subsystems meet expectations, establishing readiness for transition to pre-clinical testing.
WP7
The project was effectively managed by TU/e, with regular online and biannual in-person meetings fostering excellent collaboration among partners.
WP8
Dissemination activities targeted stakeholders, including development and exploitation plans (D7.1 D7.2). Advisory boards (AAB and SAB) were engaged to promote the uptake of results.